Revolution Medicines Inc (NASDAQ: RVMD) closed the day trading at $36.25 up 2.00% from the previous closing price of $35.54. On the day, 1191734 shares were traded.
Ratios:
For a better understanding of RVMD, let’s look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 13.06 and its Current Ratio is at 13.06. In the meantime, Its Debt-to-Equity ratio is 0.05 whereas as Long-Term Debt/Eq ratio is at 0.04.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Needham on April 12, 2024, Reiterated its Buy rating but revised its target price to $46 from $36 previously.
On April 10, 2024, Raymond James Upgraded its rating to Strong Buy which previously was Outperform and also upped its target price recommendation from $36 to $48.
On March 11, 2024, Piper Sandler started tracking the stock assigning a Overweight rating and target price of $43.Piper Sandler initiated its Overweight rating on March 11, 2024, with a $43 target price.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Apr 10 ’24 when GOLDSMITH MARK A sold 10,000 shares for $35.33 per share. The transaction valued at 353,346 led to the insider holds 30,424 shares of the business.
GOLDSMITH MARK A sold 7,500 shares of RVMD for $266,122 on Apr 10 ’24. The insider now owns 452,879 shares after completing the transaction at $35.48 per share. On Apr 10 ’24, another insider, Patel Sushil, who serves as the Director of the company, sold 2,155 shares for $37.00 each. As a result, the insider received 79,735 and left with 15,700 shares of the company.
Valuation Measures:
For the stock, the TTM Price-to-Sale (P/S) ratio is 515.55 while its Price-to-Book (P/B) ratio in mrq is 3.27.
Stock Price History:
Over the past 52 weeks, RVMD has reached a high of $38.73, while it has fallen to a 52-week low of $15.44.
Shares Statistics:
A total of 164.67M shares are outstanding, with a floating share count of 136.49M. Insiders hold about 17.13% of the company’s shares, while institutions hold 79.18% stake in the company.
Earnings Estimates
Current recommendations for the stock of the company come from 11 analysts. On average, analysts expect EPS of -$0.75 for the current quarter, with a high estimate of -$0.67 and a low estimate of -$0.85, while EPS last year was -$0.72. The consensus estimate for the next quarter is -$0.78, with high estimates of -$0.7 and low estimates of -$0.86.
Analysts are recommending an EPS of between -$2.99 and -$3.53 for the fiscal current year, implying an average EPS of -$3.19. EPS for the following year is -$3.43, with 12 analysts recommending between -$2.36 and -$4.11.
Revenue Estimates
10 analysts predict $1.44M in revenue for the current quarter. It ranges from a high estimate of $8.4M to a low estimate of –$. As of the current estimate, Revolution Medicines Inc’s year-ago sales were $7.01M, an estimated decrease of -79.50% from the year-ago figure. For the next quarter, 10 analysts are estimating revenue of $1.48M, a decrease of -61.30% over than the figure of -$79.50% in the same quarter last year. There is a high estimate of $8.82M for the next quarter, whereas the lowest estimate is –$.
A total of 12 analysts have provided revenue estimates for RVMD’s current fiscal year. The highest revenue estimate was $36.21M, while the lowest revenue estimate was –$, resulting in an average revenue estimate of $7.58M. In the same quarter a year ago, actual revenue was $11.58M, down -34.50% from the average estimate. Based on 12 analysts’ estimates, the company’s revenue will be $6.58M in the next fiscal year. The high estimate is $44.01M and the low estimate is –$. The average revenue growth estimate for next year is down -13.20% from the average revenue estimate for this year.
